On December 2, Glonghui reported that medical devices manufacturer Novocure Ltd. (NVCR.US) initially surged about 42%, with the increase now narrowing to 26.8%, marking the largest intraday increase since January 2023. Recent research results indicate that the company's cancer treatment Tumor Treating Fields for pancreatic cancer has achieved its primary endpoint. (Glonghui)
美股异动丨Novocure一度大涨约42%
US stocks fluctuate | Novocure surged about 42% at one point.
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
Hot News
Updated